BRPI0919753A2 - composição contendo palmitoil-etanolamida ultramicronizada - Google Patents

composição contendo palmitoil-etanolamida ultramicronizada

Info

Publication number
BRPI0919753A2
BRPI0919753A2 BRPI0919753A BRPI0919753A BRPI0919753A2 BR PI0919753 A2 BRPI0919753 A2 BR PI0919753A2 BR PI0919753 A BRPI0919753 A BR PI0919753A BR PI0919753 A BRPI0919753 A BR PI0919753A BR PI0919753 A2 BRPI0919753 A2 BR PI0919753A2
Authority
BR
Brazil
Prior art keywords
ultramronized
composition containing
palmitoyl ethanolamide
ethanolamide
palmitoyl
Prior art date
Application number
BRPI0919753A
Other languages
English (en)
Inventor
Francesco Della Valle
Gabriele Marcolongo
Maria Federica Della Valle
Original Assignee
Epitech Group Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42211652&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0919753(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Epitech Group Srl filed Critical Epitech Group Srl
Publication of BRPI0919753A2 publication Critical patent/BRPI0919753A2/pt
Publication of BRPI0919753B1 publication Critical patent/BRPI0919753B1/pt
Publication of BRPI0919753B8 publication Critical patent/BRPI0919753B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C07C231/24—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Dispersion Chemistry (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0919753A 2009-09-07 2009-09-07 forma polimórfica de palmitoiletanolamida, composição farmacêutica para uso humano ou veterinário, método para a micronização da palmitoiletanolamida e palmitoiletanolamida ultramicronizada BRPI0919753B8 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IT2009/000399 WO2011027373A1 (en) 2009-09-07 2009-09-07 Composition containing ultra-micronized palmitoyl - ethanolamide

Publications (3)

Publication Number Publication Date
BRPI0919753A2 true BRPI0919753A2 (pt) 2015-12-08
BRPI0919753B1 BRPI0919753B1 (pt) 2020-12-29
BRPI0919753B8 BRPI0919753B8 (pt) 2021-05-25

Family

ID=42211652

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0919753A BRPI0919753B8 (pt) 2009-09-07 2009-09-07 forma polimórfica de palmitoiletanolamida, composição farmacêutica para uso humano ou veterinário, método para a micronização da palmitoiletanolamida e palmitoiletanolamida ultramicronizada

Country Status (14)

Country Link
US (2) US8470373B2 (pt)
EP (2) EP2796129B1 (pt)
JP (1) JP5746178B2 (pt)
KR (1) KR101662871B1 (pt)
CN (2) CN102186459A (pt)
AR (2) AR078159A1 (pt)
AU (1) AU2009352080B2 (pt)
BR (1) BRPI0919753B8 (pt)
CA (1) CA2738117C (pt)
CY (2) CY1116698T1 (pt)
ES (2) ES2548190T3 (pt)
PL (2) PL2475352T5 (pt)
PT (2) PT2796129E (pt)
WO (1) WO2011027373A1 (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110178151A1 (en) 2008-03-04 2011-07-21 Yissum Research Development Company Of The Hebrew Compounds and methods of treating obesity
ES2548190T3 (es) 2009-09-07 2015-10-14 Epitech Group S.P.A. Composición que contiene palmitoiletanolamida ultramicronizada
WO2014013497A1 (en) * 2012-07-20 2014-01-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Fatty acid derivatives for use in a method of treating depression and associated conditions
ITMI20130354A1 (it) 2013-03-08 2014-09-09 Again Life Italia Srl Miscela di acidi grassi (f.a.g. fatty acids group) per uso nel trattamento di patologie infiammatorie.
US20190290609A1 (en) 2014-03-19 2019-09-26 Epitech Group S.P.A. Pharmaceutical composition comprising palmitoylethanolamide and l-acetylcarnitine
ES2603809T3 (es) 2014-03-19 2017-03-01 Epitech Group S.R.L. Composición farmacéutica que comprende palmitoiletanolamida y L-acetilcarnitina
EP2921171B1 (en) * 2014-03-21 2019-10-16 EPITECH GROUP S.p.A. Ophthalmic, intra-articular or intravesical preparations containing N-acyl-ethanolamines
TR201908936T4 (tr) * 2014-05-14 2019-07-22 Epitech Group S P A Opioidler ile kombinasyon halinde palmitoiletanolamid kullanımı.
US20160008301A1 (en) 2014-07-08 2016-01-14 Epitech Group S.R.L. Use of Adelmidrol in the Treatment of Epithelial Dysfunctions
EP2985037B1 (en) 2014-08-13 2017-06-21 EPITECH GROUP S.p.A. A pharmaceutical composition comprising palmitoylethanolamid and cytidine-diphosphocholine
JP2015155412A (ja) * 2015-03-03 2015-08-27 エピテック・グループ・エス．アール．エル． 超微粉化パルミトイル−エタノールアミドを含む組成物
NL2014464B1 (en) 2015-03-16 2017-01-13 Vanderbilt Science Holding Ltd Composition for use in the treatment of neuropathic pain.
JP6938465B2 (ja) * 2015-04-29 2021-09-22 エスシーアイ スパーク リミティド カンナビノイドとｎ−アシルエタノールアミンの組み合わせ
WO2016183134A1 (en) * 2015-05-12 2016-11-17 Cutting Edge Medical Solutions, Llc Palmitoylethanolamide compositions
ITUB20153066A1 (it) 2015-08-11 2017-02-11 Graal S R L Composizione alimentare e/o nutraceutica contenente pea
WO2017025588A1 (en) * 2015-08-11 2017-02-16 Eyesiu Medicines B.V. Pegylated lipid nanoparticle with bioactive lipophilic compound
ITUB20154849A1 (it) * 2015-10-30 2017-04-30 Epitech Group S P A ADELMIDROL PER L'USO NELLE PATOLOGIE CARATTERIZZATE DA INSUFFICIENTE AGONISMO DEL RECETTORE PPAR-gamma
ES2580508B1 (es) * 2016-04-11 2018-09-12 Servicio Andaluz De Salud Composiciones para la prevención y/o tratamiento de los trastornos por uso de alcohol.
NL2017559B1 (en) * 2016-09-30 2018-04-10 Vanderbilt Science Holding Ltd Method for preparing pulverized palmitoylethanolamide particles, particles obtainable by the method, and apharmaceutical or neutraceutical composition comprising saidparticles
CN106478445A (zh) * 2016-11-07 2017-03-08 华中药业股份有限公司 一种非那西丁微粉的制备方法
EP3417846A1 (en) 2017-06-19 2018-12-26 Gifar Srl Food and/or nutraceutical composition
IT201700068608A1 (it) * 2017-06-20 2018-12-20 Neilos S R L Composizione per trattamento o prevenzione di una malattia neurodegenerativa
SG10201802129QA (en) * 2017-07-05 2019-02-27 Frimline Private Ltd A pharmaceutical composition for neuropathic pain
US20220112625A1 (en) * 2017-09-02 2022-04-14 Richard Postrel Diagnosing and Treating Neurological and Autoimmune Diseases by Optimizing Metabolic Responses
PH12018000227B1 (en) 2017-09-05 2019-03-11 Frimline Private Ltd A pharmaceutical composition for improving or preventing progression of chronic kidney disease
IT201800003912A1 (it) * 2018-03-26 2019-09-26 Innovet Italia Srl N-palmitoil-d-glucosamina in forma micronizzata
IT201800004439A1 (it) * 2018-04-12 2019-10-12 ASSOCIAZIONE DI CURCUMA (Curcuma longa L.), PALMITOILETANOLAMIDE (PEA) E L-TRIPTOFANO
WO2021048871A1 (en) * 2019-09-15 2021-03-18 Celagenex Research (India) Pvt. Ltd. Synergistic bioactive compositions for treating neurological disorders
EP3838346A1 (en) * 2019-12-20 2021-06-23 Chemo Research SL Soft gelatin capsules comprising palmitoylethanolamide and alpha-lipoic acid
US11684600B2 (en) * 2020-03-04 2023-06-27 Compact Disc Incorporated Composition of active agents to positively affect a robust mammalian endocannabinoid system tone to better address age related discomfort
IT202000007831A1 (it) 2020-04-14 2021-10-14 Epitech Group S P A Adelmidrol per l’uso nel trattamento della fibrosi polmonare
GR20200100479A (el) * 2020-08-13 2022-03-09 Pharma Unimedis Ike, Συμπληρωμα διατροφης για την προληψη και/ή τη θεραπεια του πονου και/ή νευροπαθειων
CN115052587B (zh) * 2020-12-29 2024-05-10 汉义生物科技（北京）有限公司 一种大麻素泡腾制剂及其制备方法
IT202100006494A1 (it) * 2021-03-18 2022-09-18 Epitech Group S P A N-palmitoil-etanolamide per l’uso nella prevenzione del carcinoma colo-rettale
IT202100015278A1 (it) 2021-06-11 2022-12-11 Epitech Group S P A Composizione di n-palmitoil-etanolamide e baicaleina in forma comicronizzata
IT202100024464A1 (it) * 2021-09-23 2023-03-23 Epitech Group S P A N-palmitoil-etanolamide e acido docosaesaenoico per l’uso nel trattamento del disturbo dello spettro autistico e di altre sindromi depressive
WO2023133555A2 (en) * 2022-01-10 2023-07-13 Zilker Sciences Llc Palmitoylethanolamide treatment for covid-19-related inflammation
IT202200011957A1 (it) * 2022-06-07 2023-12-07 Erbozeta S P A Associazione tra PEA e melatonina per il trattamento di dolore e infiammazione
IT202200017820A1 (it) * 2022-08-30 2024-03-01 Unifarco S P A Compressa nutraceutica comprendente palmitoiletanolamide
IT202300003828A1 (it) * 2023-03-02 2024-09-02 Soal Pharma Srl Integratore alimentare per il trattamento del dolore neuropatico
IT202300021465A1 (it) * 2023-10-16 2025-04-16 Fenix Pharma Soc Cooperativa Miscele multicomponenti, composizioni contenenti tali miscele e loro uso nel trattamento di acufeni e neuropatie periferiche
IT202400003373A1 (it) 2024-02-16 2025-08-16 Pharma Line S R L Composizione utile per il trattamento del dolore neuropatico
CN119015425A (zh) * 2024-09-10 2024-11-26 中国科学技术大学 Naaa在预防或治疗脑卒中或卒中后焦虑中的应用
WO2026149869A1 (en) 2025-01-09 2026-07-16 Indena S.P.A. Composition containing n-acylethanolamide

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2627696B1 (fr) 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
AU3564589A (en) 1988-05-17 1989-12-12 Liposome Technology, Inc. Preparation of uniform-size liposomes and other lipid structures
IT1252865B (it) 1991-12-31 1995-06-28 Lifegroup Spa N-acilderivati di aminoalcooli attivi come autocoidi locali ed utilizzabili nella terapia dei processi autoimmuni
US5679667A (en) 1992-04-24 1997-10-21 Lifegroup S.P.A. Aminoalcohols-N-Acyl derivatives as therapeutical agents against the neurogenic endoneural edema of the peripheral nerve
WO1994028876A1 (en) 1993-06-07 1994-12-22 Advanced Therapies, Inc. Liposome powders
US5622715A (en) 1994-06-10 1997-04-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of improving renal function
US5567439A (en) * 1994-06-14 1996-10-22 Fuisz Technologies Ltd. Delivery of controlled-release systems(s)
IT1271266B (it) * 1994-12-14 1997-05-27 Valle Francesco Della Impiego terapeutico di ammidi di acidi mono e bicarbossilici con amminoalcoli,selettivamente attive sul recettore periferico dei cannabinoidi
US5874029A (en) 1996-10-09 1999-02-23 The University Of Kansas Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent
IT1302264B1 (it) † 1998-09-24 2000-09-05 Innovet Italia Srl Derivati a struttura n-acil vanillinamidica in grado di attivare irecettori periferici dei cannabinoidi
WO2001010434A1 (en) * 1999-08-06 2001-02-15 Innovet Italia S.R.L. Pharmaceutical compositions containing n-palmitoylethanolamide and use thereof in the veterinary field
US20090203134A1 (en) 2005-01-18 2009-08-13 Kyoto University Remedy for nerve cell regeneration
DE602006013787D1 (de) * 2006-03-28 2010-06-02 Epitech Group Srl Eine Pharmazeutische Zusammensetzung zur Behandlung von Pathologien, die durch die allgemeine Immunantwort verursacht werden
NZ552290A (en) 2006-12-21 2009-05-31 Bomac Research Ltd Tablet fomulation
ES2548190T3 (es) 2009-09-07 2015-10-14 Epitech Group S.P.A. Composición que contiene palmitoiletanolamida ultramicronizada

Also Published As

Publication number Publication date
AR115939A2 (es) 2021-03-17
CN106138022A (zh) 2016-11-23
US8470373B2 (en) 2013-06-25
WO2011027373A1 (en) 2011-03-10
ES2547133T3 (es) 2015-10-02
BRPI0919753B1 (pt) 2020-12-29
US20110171313A1 (en) 2011-07-14
EP2475352B2 (en) 2018-09-05
PT2475352E (pt) 2015-10-13
PL2475352T5 (pl) 2019-02-28
EP2475352A1 (en) 2012-07-18
AR078159A1 (es) 2011-10-19
AU2009352080A1 (en) 2013-06-06
KR20120093861A (ko) 2012-08-23
JP5746178B2 (ja) 2015-07-08
AU2009352080B2 (en) 2015-12-24
EP2796129B1 (en) 2015-06-17
US8663701B2 (en) 2014-03-04
CY1116695T1 (el) 2017-03-15
ES2548190T3 (es) 2015-10-14
EP2796129A1 (en) 2014-10-29
CA2738117A1 (en) 2011-03-10
US20130280333A1 (en) 2013-10-24
PT2796129E (pt) 2015-10-13
JP2013503855A (ja) 2013-02-04
CN102186459A (zh) 2011-09-14
BRPI0919753B8 (pt) 2021-05-25
PL2475352T3 (pl) 2016-01-29
CA2738117C (en) 2016-12-06
PL2796129T3 (pl) 2015-11-30
KR101662871B1 (ko) 2016-10-05
CY1116698T1 (el) 2017-03-15
ES2547133T5 (es) 2019-02-15
EP2475352B1 (en) 2015-06-17
ES2547133T9 (es) 2016-01-22

Similar Documents

Publication Publication Date Title
SMT201600307B (it) Composizione liposomiale
BRPI1013588A2 (pt) composição
DK3078664T3 (da) Antiparasitiske dihydroazol-sammensætninger
BRPI1015474A2 (pt) composição
EP2488022A4 (en) Compositions
PT2593094T (pt) Composição aquosa contendo bromexina
UY33161A (es) Composiciones plaguicidas
SMT201500053B (it) 2-Amminobenzimidazol-5-carbossammidi come agenti nati-infiammatori
DOP2011000396A (es) Composiciones novedosas
BRPI1006125A2 (pt) óculos
DK2462134T3 (da) N1-sulfonyl-5-fluorpyrimidinonderivater
BRPI1010690A2 (pt) composições
BR112012007952A2 (pt) composição detergente
EP2488586A4 (en) HARDENING COMPOSITION
EP2495286A4 (en) HARDENING COMPOSITION
EP2513226A4 (en) HALOGEN-FREE FLAME RETARDANT COMPOSITIONS
EP2455446A4 (en) CLEANING AGENT COMPOSITION
BR112012005039A2 (pt) Composição detergente
EP2476732A4 (en) ELECTRICALLY CONDUCTIVE COMPOSITION
BRPI1006239A2 (pt) composição curável contendo diamina
DK2985033T3 (da) Faktor vii-sammensætning
EP2516011A4 (en) CARRIER COMPOSITION
EP2479211A4 (en) FLUOR RUBBER COMPOSITION
BRPI1005318A2 (pt) composição
BRPI0917563A2 (pt) porta-objeto

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 3A. ANUIDADE(S)

B08G Application fees: restoration [chapter 8.7 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/12/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/09/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF